The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine
kinases (RTK). These trans-membrane proteins are activated following binding with peptide …

Introduction: The RAS/RAF/MAP kinase–ERK kinase (MEK)/extracellular-signal-regulated
kinase (ERK) (MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR) (PI3K) …

The epidermal growth factor receptor (EGFR) family comprehends four different tyrosine
kinases (EGFR, ErbB‐2, ErbB‐3, and ErbB‐4) that are activated following binding to epidermal …

Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of
angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly targeting …

We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast
carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the …

A range of target‐based agents for the treatment of solid tumors are in development. The
epidermal growth factor receptor (EGFR) has been identified as a relevant target as it is …

The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source
of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing …

Identification of molecular alterations in key proteins involved in breast cancer cell
proliferation and survival resulted in the development of a new treatment strategy with target-based …

Significant relief of bone pain in patients with bone metastases was observed in a clinical trial
of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in breast …

Background: Colorectal cancer (CRC) is the second most common cause of cancer-specific
death in both sexes in Western countries. KRAS mutations occur in about 50% of metastatic …